Brown Advisory
CRNX icon

Brown Advisory’s Crinetics Pharmaceuticals CRNX Stock Holding History

Brown Advisory’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,585
Closed -$471K – 1145
2021
Q4 		$471K Buy
+16,585
New +$409K ﹤0.01% 893

Other funds holding CRNX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Brown Advisory's CRNX Position: Q1 2022 in Review

Brown Advisory sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2022, closing a stake of 16,585 shares — an estimated $471K sold.

Brown Advisory first reported a position in CRNX in Q4 2021 and held it in 1 quarter. The position peaked at $471K in Q4 2021. 116 funds tracked by Wall St. Rank hold CRNX as of Q1 2022.

  • Brown Advisory reported no remaining Crinetics Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Brown Advisory sold 16,585 Crinetics Pharmaceuticals shares in Q1 2022, an estimated $471K.
  • Brown Advisory first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Brown Advisory's Crinetics Pharmaceuticals position peaked at $471K in Q4 2021.
  • 116 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.